Dual blockade of PD-1 and CTLA-4 generates long-lasting immunity against irradiated glioblastoma
Cancer Letters · 2025-09 · 628 · 217856
DOI: 10.1016/j.canlet.2025.217856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-09. Verfasst von Mara De Martino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Glioblastoma, Programmed Cell Death 1 Receptor, CTLA-4 Antigen, Brain Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Institute of Neurological Disorders and Stroke, National Cancer Institute, Weill Cornell Medicine.
Abstract (Originalsprache)
Radiation therapy (RT) can release pro-inflammatory signals to jumpstart an anti-tumor immune response. However, glioblastoma (GBM) often recurs, suggesting that RT might not act as an immune adjuvant in this disease. A possible explanation for the lack of immune stimulation is the use of irradiation regimens that do not effectively stimulate anti-tumor immunity against GBM. Here, we tested the ability of various RT schedules to elicit type I interferon (IFN-I) response and explored its synergy with immunotherapy (IT) to trigger anti-tumor immunity against GBM. Using three murine GBM models, we show in vitro that single dose radiation ranging from 0Gy to 20Gy and fractionated radiation schedules (i.e. 3 daily fractions of 8Gy; 3 × 8Gy and 5 daily fractions of 6Gy; 5 × 6Gy) accumulates double stranded DNA and release IFN-I related cytokines in a dose-dependent fashion; with fractionated schedules being superior in triggering cancer-cell intrinsic IFN-I responses. Side-by-side comparison of various radiation regimen in vivo revealed that 5 × 6Gy better control GBM across the three GBM models tested. However, the addition of anti-PD1 or anti-CTLA4 to an immunogenic radiation schedule (i.e. 5 × 6Gy) did not prolong survival of irradiated mice. Surprisingly, only the dual blockade of PD-1 and CTLA4 promoted the expansion of proliferative T cells and conveyed immunological memory against irradiated GBM. Overall, this study demonstrates that an immunogenic radiation regimen is not sufficient to mount an anti-tumor immune response when combine with IT as monotherapy and highlights the need to combine an immunogenic irradiation with multiple IT to overcome immunosuppression of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center, 10065, New York, NY, USA. Electronic address: clv2002@med.cornell.edu.
Förderung
- National Institute of Neurological Disorders and Stroke
- National Cancer Institute
- Weill Cornell Medicine
- National Institutes of Health
- Brain Tumor Charity
- Uncle Kory Foundation
Zitieren
APA
De Martino, M., Daviaud, C., Lira, M. C., Hernandez-Zirofsky, K., & Vanpouille-Box, C. (2025). Dual blockade of PD-1 and CTLA-4 generates long-lasting immunity against irradiated glioblastoma. Cancer Letters, 628, 217856. https://doi.org/10.1016/j.canlet.2025.217856
Vancouver
De Martino M, Daviaud C, Lira MC, Hernandez-Zirofsky K, Vanpouille-Box C. Dual blockade of PD-1 and CTLA-4 generates long-lasting immunity against irradiated glioblastoma. Cancer Letters. 2025;628:217856. doi:10.1016/j.canlet.2025.217856
BibTeX
@article{DeMartino2025,
author = {De Martino, Mara and Daviaud, Camille and Lira, María Cecilia and Hernandez-Zirofsky, Kayla and Vanpouille-Box, Claire},
title = {Dual blockade of PD-1 and CTLA-4 generates long-lasting immunity against irradiated glioblastoma},
journal = {Cancer Letters},
year = {2025},
volume = {628},
pages = {217856},
doi = {10.1016/j.canlet.2025.217856}
}
EUVIMED